Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MAIA Biotechnology, Inc.

< Previous 1 2 Next >
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Share Repurchase Program
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology, Inc. Announces Closing of Public Offering
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology, Inc. Announces Pricing of Public Offering
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present at AACR Annual Meeting 2023
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces No Exposure to Silicon Valley Bank
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
ADDING MULTIMEDIA: MAIA Biotechnology’s Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Advances New Telomere-Targeting Molecule Program
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Participate in Four Upcoming Investor Conferences
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback